• Journal of Veterinary Clinics
• /
• v.37 no.6
• /
• pp.317-323
• /
• 2020

The aims of this study were to describe the appearance and size of the normal canine prostate using magnetic resonance (MR) imaging and to calculate the apparent diffusion coefficient (ADC) values. MR images were obtained from seven intact male beagle dogs using a 1.5 T MR unit. The sequences included pre- and post-contrast T1- and T2-weighted imaging with and without fat saturation. The signal intensity of the prostate was compared with the adjacent musculature, fat, and urine in the urinary bladder. We recorded the mean prostatic length, width, and height and the length of the sixth lumbar vertebral body (L6). In addition, the prostatic length (rL), width (rW), and height (rH) ratios to L6 were calculated. Diffusion-weighted images of the prostate were obtained and ADC values were calculated. The prostate was bilobed and oval-shaped, homogenous on T1-weighted images, and heterogeneous with radiating lines on T2-weighted images. Post-contrast T1-weighted sequences showed contrast enhancement of the central and radiating striations. The prostatic capsule was clearly identified on post-contrast T1-weighted images with fat saturation. The ADC values were 1.72-2.04 × 10-3mm2/sec (mean, 1.88 × 10-3mm2/sec). Knowledge of the normal appearance of the prostate on MR images is essential to assess prostatic diseases in dogs.

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.5
• /
• pp.1857-1863
• /
• 2015

Background: Alpha-methylacyl-CoA racemase(AMACR) is thought to play key roles in diagnosis and prognosis of prostate cancer. However, studies of associations between AMACR gene polymorphisms and prostate cancer risk reported inconsistent results. Therefore, we conducted the present meta-analysis to clarify the link between AMACR gene polymorphisms and prostate cancer risk. Materials and Methods: A literature search was performed in PubMed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang and Weipu databases. Odds ratios (ORs) and 95% confidence intervals (95%CIs) were calculated to assess the strength of any association between AMACR polymorphisms and prostate cancer risk. Subgroup analyses by ethnicity, source of controls, quality control and sample size were also conducted. Results: Five studies covering 3,313 cases and 3,676 controls on five polymorphisms (D175G, M9V, S201L, K277E and Q239H) were included in this meta-analysis. Significant associations were detected between prostate cancer and D175G (dominant model: OR=0.89, 95%CI=0.80-0.99, P=0.04) and M9V (dominant model: OR=0.87, 95%CI=0.78-0.97, P=0.01) polymorphisms as well as that in subgroup analyses. We also observed significant decreased prostate cancer risk in the dominant model (OR=0.90, 95%CI=0.81-0.99, P=0.04) for the S201L polymorphism. However, K277E and Q239H polymorphisms did not appear to be related to prostate cancer risk. Conclusions: The current meta-analysis indicated that D175G and M9V polymorphisms of the AMACR gene are related to prostate cancer. The S201L polymorphism might also be linked with prostate cancer risk to some extent. However, no association was observed between K277E or Q239H polymorphisms and susceptibility to prostate cancer.

• KIPS Transactions on Software and Data Engineering
• /
• v.1 no.3
• /
• pp.187-194
• /
• 2012

Prostate cancer is one of the most frequent cancers in men and is a major cause of mortality in the most of countries. In many diagnostic and treatment procedures for prostate disease, transrectal ultrasound(TRUS) images are being used because the cost is low. But, accurate detection of prostate boundaries is a challenging and difficult task due to weak prostate boundaries, speckle noises and the short range of gray levels. This paper proposes a method for automatic prostate segmentation in TRUS images using its average shape model and invariant features. This approach consists of 4 steps. First, it detects the probe position and the two straight lines connected to the probe using edge distribution. Next, it acquires 3 prostate patches which are in the middle of average model. The patches will be used to compare the features of prostate and nonprostate. Next, it compares and classifies which blocks are similar to 3 representative patches. Last, the boundaries from prior classification and the rough boundaries from first step are used to determine the segmentation. A number of experiments are conducted to validate this method and results showed that this new approach extracted the prostate boundary with less than 7.78% relative to boundary provided manually by experts.

• Journal of radiological science and technology
• /
• v.38 no.4
• /
• pp.437-442
• /
• 2015

Accurate volume measurement of the prostate is a significant role in determining the result of diagnosis and treatment of benign prostate hyperplasia. The purpose of this study was to determine, when measuring prostate volume by TRUS, whether location is more accurately determined by transaxial or longitudinal scanning. With reference to the patient's image, it was produced six prostate model. It compares the actual volume and the measurement volume, and find the optimal measurement position of each specific model. Prostate volume measured by TRUS closely correlates with prostate phantom volume. There was no significant difference(p = .156). To measure the accurate volume of prostate with focal protrusion, its length should be measured exclude the protrusions.

• The Korean Journal of Rehabilitation Nursing
• /
• v.7 no.1
• /
• pp.78-87
• /
• 2004

Purpose: The purpose of this study was to identify relationship of urinary symptom, urinary discomfort and quality of life among the bladder cancer patients and benign prostate hypertrophy patients, and to contribute health promotion of such patients and nursing intervention development based on this results. Method: Study sample recruited bladder cancer patents(n=49) and benign prostate hypertrophy patients who admitted Seoul National University Hospital from June, 2002 to June, 2003. Both group patients were operated, and prostate hypertrophy patients group (mean 67.8 years old) were older than bladder cancer patients group(60.82 years old). Instruments was composed of general characteristics, urinary symptom scale(19 items), urinary discomfort scale(19 items) and quality of life scale(21 items). Data was analysed SPSS PC + 10. using mean, standard deviation, pearson correlation coefficient. Result as follows: 1. There was a statistically significant difference in occupation between two groups (p=.027). Hypertrophy patients group's age was more older than bladder cancer patients group. 2. The prostate hypertrophy patients group had the significantly higher score in urinary symptom (p=000) and nighttime urination frequency. However, there was no significant difference in incontinence symptoms and the symptoms associated bladder cancer between two groups. 3. The prostate hypertrophy patients group had significantly higher score in urinary discomfort (p=000) than the bladder cancer patients group. However, there was no significant difference incontinence discomfort and the discomfort associated bladder cancer between two groups. 4. The prostate hypertrophy patients group suffered more urinary discomfort than the bladder cancer patients group did. The quality of life the prostate hypertrophy patients group was lower than the quality of life the bladder cancer patients group. Quality of life was no statistically significant difference between two groups (p=000). 5. There was a positive correlation between urinary symptoms and urinary discomfort. However, there was a negative correlation between the quality of life and urination symptoms and discomfort. Conclusions: The prostate hypertrophy patients group had significantly higher score in urinary symptom and urinary discomfort (p=000) than the bladder cancer patients group. The quality of life the prostate hypertrophy patients group was lower than the quality of life the bladder cancer patients group. This means that urinary symptom and urinary discomfort in prostate hypertrophy patient group is more important problem. So, prostate hypertrophy patient group need to control the symptom. Therefore, nurses will be provide the intervention program to improve the bladder function after prostate hypertrophy surgery.

• Journal of Yeungnam Medical Science
• /
• v.22 no.2
• /
• pp.199-210
• /
• 2005

Background: The role of obesity in prostate cancer etiology remains controversial. The aim of this study was to evaluate the relationship between obesity and prostate cancer risk. Materials and methods: Between January 2000 and June 2005, 286 patients suspected of having prostate cancer underwent prostate biopsy. The clinical records of the 286 study patients were retrospectively reviewed with regard to age, Body Mass Index (BMI), serum PSA, TRUS, and prostate biopsy results. They were stratified by BMI into three groups according to the cutoffs recommended for Asian populations: normal, BMI less than 23 $kg/m^2$; overweight, BMI 23 to 25 $kg/m^2$; and obese, BMI greater than 25 $kg/m^2$. Results: As for BMIs, 132 (46.2%) were normal, 95 (33.2%) overweight and 59 (20.6%) were obese. A total of 99 (34.6%) patients were diagnosed as having prostate cancer. In multivariate logistic regression analyses, no significant association was observed between BMI and prostate cancer detection. Conclusion: We initially hypothesized that obesity may be biologically associated with increased prostate cancer development. However, our study did not show a significant association between BMI and prostate cancer.

• Proceedings of the Korean Biophysical Society Conference
• /
• 2001.06a
• /
• pp.44-44
• /
• 2001

Neuroendocrine (NE) cells are abundant in the prostate at birth and then disappear from the peripheral zone, only to reappear during puberty, after which their number slowly increases during adult life. NE cells are believed to play an important role in prostate growth and differentiation. The present study was undertaken to investigate the characteristics of ion channels existing in NE cells of rat prostate gland.(omitted)

• Journal of Veterinary Clinics
• /
• v.31 no.3
• /
• pp.175-179
• /
• 2014

The purpose of this study was to determine and compare prostate size using ultrasound and computed tomography (CT). The prostate gland was evaluated in eight normal Beagle dogs. Length, depth, and width of the prostate gland were measured by ultrasound and volume of the prostate was obtained from the two ellipsoid formula (US1, US2). Height, length, width, area, and volume of the prostate gland were measured by CT. Ratios of prostatic height, length, and width to the sixth lumbar vertebral body length were calculated. There was no significant difference between the US1 and US2 method, and between US2 and CT method, respectively. The prostatic volume calculated by US1 method was significantly lower than those with CT (p=0.029). The Upper limits of ratios of prostate length, height, and width to the length of the sixth lumbar vertebra were 1.3, 1.1, and 1.7, respectively. Among these prostate dimensions, prostate length and height could be a useful index in estimating prostate size regardless of body weight.

• Nutrition Research and Practice
• /
• v.11 no.5
• /
• pp.373-380
• /
• 2017

BACKGROUND/OBJECTIVES: This study was conducted to investigate the effect of a corn silk extract on improving benign prostatic hyperplasia (BPH). MATERIALS/METHODS: The experimental animals, 6-week-old male Wistar rats, were divided into sham-operated control (Sham) and experimental groups. The experimental group, which underwent orchiectomy and received subcutaneous injection of 10 mg/kg of testosterone propionate to induce BPH, was divided into a Testo Only group that received only testosterone, a Testo+Fina group that received testosterone and 5 mg/kg finasteride, a Testo+CSE10 group that received testosterone and 10 mg/kg of corn silk extract, and a Testo+CSE100 group that received testosterone and 100 mg/kg of corn silk extract. Prostate weight and concentrations of dihydrotestosterone (DHT), $5{\alpha}$- reductase $2(5{\alpha}-R2)$, and prostate specific antigen (PSA) in serum or prostate tissue were determined. The mRNA expressions of $(5{\alpha}-R2)$ and proliferating cell nuclear antigen (PCNA) in prostate tissue were also measured. RESULTS: Compared to the Sham group, prostate weight was significantly higher in the Testo Only group and decreased significantly in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups (P < 0.05), results that were consistent with those for serum DHT concentrations. The concentrations of $(5{\alpha}-R2)$ in serum and prostate as well as the mRNA expression of $(5{\alpha}-R2)$ in prostate were significantly lower in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups than that in the Testo Only group (P < 0.05). Similarly, the concentrations of PSA in serum and prostate were significantly lower in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups (P < 0.05) than in the Testo Only group. The mRNA expression of PCNA in prostate dose-independently decreased in the Testo+CSE-treated groups (P < 0.05). CONCLUSIONS: BPH was induced through injection of testosterone, and corn silk extract treatment improved BPH symptoms by inhibiting the mRNA expression of $(5{\alpha}-R2)$ and decreasing the amount of $(5{\alpha}-R2)$, DHT, and PSA in serum and prostate tissue.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.8
• /
• pp.3931-3936
• /
• 2012

Background: Epidemiological studies evaluating the association of two variants rs9340799 and rs2234693 on estrogen receptor 1 (ESR1) with prostate risk have generated inconsistent results. Methods: A meta-analysis was here conducted to systematically evaluate the relationship of these two variants with prostate cancer susceptibility. Results: For rs9340799, heterozygosity of T/C carriers showed a significant increased prostate cancer risk with a pooled odds ratio (OR) of 1.34 (95% CI = 1.06-1.69) while homozygote C/C carriers showed an increased but not statistically significant association with prostate cancer risk (pooled OR = 1.29, 95% CI = 0.94-1.79). Compared to the homozygous TT carriers, the allele C carriers showed a 31% increased risk for prostate cancer (pooled OR = 1.31, 95% CI = 1.06-1.63). No significant association between the rs2234693 and prostate cancer risk was found with the pooled OR of 1.15 (95% CI = 0.97-1.39, T/C and C/C vs. T/T) under the dominant genetic model. Compared to the homozygote T/T carriers, the heterozygous T/C carriers did not show any significantly different risk of prostate cancer (pooled OR = 1.13, 95% CI = 0.94-1.36) and the homozygous C/C carriers also did not show a significant change for prostate cancer risk compared to the wide-type T/T carriers (pooled OR = 1.26, 95% CI = 0.98-1.62). Conclusion: These data suggested that variant rs9340799, but not rs2234693, on ESR1 confers an elevated risk of prostate cancer.